The purchase price, which is confidential & was negotiated for a maximum of 300 zillion doses, is slightly lower than the $19.50 a picture the United States agreed to pay for a very first shipment of 100 million doses of the same vaccine, in line with what Reuters claimed in November.
The EU file dated Nov. 18 was circulated internally right after the EU announced its supply package with Pfizer and its German partner BioNTech on Nov. 11.
The EU drug regulator is actually likely to determine on Monday on acceptance for the Pfizer vaccine after the shot was authorised in a few countries, including Britain and the United States.
On Thursday Belgian state secretary for the budget Eva De Bleeker released on Twitter a dinner table with price tags Belgium will pay pharmaceutical companies for the COVID 19 vaccines of theirs. She retracted the piece of writing shortly after publishing.
In this table the Pfizer vaccine was indicated as costing Belgium twelve euros ($14.6) per dose, top many to think this was the full price agreed with the EU.
Various other vaccines in the table were furthermore shown with rates lower compared to prices disclosed by EU sources.
“There is , obviously , a complete cost and a price upon delivery,” an EU official required in talks with vaccine creators told Reuters when directed to clarify the difference between the EU and Belgian rates.
A spokesman for De Bleeker declined to comment on Monday, citing confidentiality requirements, but pointed to what De Bleeker told the Belgian parliament last week. In that public hearing, De Beeker said Belgium’s budgeted costs were still partial.
Underneath EU prior purchase deals for COVID 19 vaccines, the bloc agrees initial payments with businesses to secure doses before they’re approved. After approvals, EU governments are able to pay the remainder to purchase reserved doses.
The EU hasn’t revealed the initial transaction agreed with Pfizer.
Nonetheless, it mentioned in October which it paid aproximatelly one billion euros in downpayments to AstraZeneca, Sanofi and Johnson and Johnson for the shots of theirs, with an additional 1.45 billion euros budgeted for upfront payments to Pfizer-BioNTech, Moderna and Curevac.
It has since agreed supply deals with all 6 businesses and it is negotiating a seventh understanding with Novavax.